Semaglutide Pharmacology: What the Evidence Tells Us About How It Works

Why a copy of a gut hormone can last a whole week

The body's own GLP-1 is cleared from the bloodstream within one to two minutes. That's useful for moment-to-moment appetite signalling after a meal, but useless as a medicine, you'd need continuous infusions to see any therapeutic effect. Semaglutide solves this by attaching a fatty-acid chain to the GLP-1 peptide backbone, which binds loosely to albumin (a protein that circulates in the blood). That molecular tethering protects semaglutide from the enzymes that quickly degrade natural GLP-1, extending its half-life to roughly seven days. One weekly injection delivers a stable, sustained level of receptor activity. The pharmacokinetics of semaglutide (how it moves through and leaves the body) are worth understanding if you want a clearer picture of dosing rationale.

This longevity also explains the titration schedule. Starting at a low dose gives the body time to adjust to continuous GLP-1 receptor stimulation; most of the nausea people notice early on settles as the system adapts. The prescriber, not the patient, decides the pace of that escalation.

Three sites where semaglutide does its work

Semaglutide's effects don't happen in one place. In the pancreas, it stimulates insulin release when blood glucose rises and suppresses glucagon, the hormone that pushes glucose upward. In people without diabetes, this keeps blood sugar in a narrow range without causing hypoglycaemia at normal doses, because the insulin response is glucose-dependent. In the hypothalamus (the brain region that integrates appetite signals) GLP-1 receptors receive semaglutide's signal and reduce hunger drive. Patients commonly describe this as a quieting of food noise: the persistent background urge to eat simply becomes less loud. In the gastrointestinal tract, slowed gastric emptying means food leaves the stomach more slowly, extending the feeling of fullness after a smaller meal.

The NHS medicines information for semaglutide covers these mechanisms at a patient level, and it's a reliable starting point if you want to read the official summary alongside this.

If you're curious how this compares with tirzepatide's dual-receptor approach, the pharmacology overview on the Wegovy treatment page sets out the distinctions without oversimplifying them.

What the STEP trial data actually showed, and what it doesn't tell you

The STEP 1 trial, published in the New England Journal of Medicine, randomised 1,961 adults with obesity to semaglutide 2.4 mg or placebo over 68 weeks, alongside lifestyle intervention. Average weight reduction in the semaglutide group was around 15%, compared with about 2.4% with placebo. That's a meaningful difference, but trial averages are exactly that: averages. Some participants lost considerably more; others lost less. Individual response depends on genetics, baseline weight, adherence, diet and a range of factors a pharmacist can't predict from a population study.

It's worth being honest about what pharmacology can't tell you on its own. Knowing the mechanism explains why the drug works in the right candidates. It doesn't tell you whether you are one of them. That's what a clinical consultation is for, and it's the question our clinical team reviews carefully before any prescription is issued. If you're weighing up treatment options more broadly, the weight-loss treatment overview sets out what's currently licensed in the UK.

One thing the evidence is clear on: semaglutide is not assessed by the MHRA for quick or cosmetic weight loss, and this is not how the licensed medicine is intended to be used. The Wegovy information page goes into the licensed indications in detail, including the BMI and comorbidity criteria that determine whether treatment is clinically appropriate. Cost is a practical consideration for many people; the Wegovy cost page covers what private treatment typically involves.

Side effects that follow from the mechanism

If you understand how semaglutide works, most of the common side effects make immediate sense. Slowed gastric emptying produces nausea, fullness after small portions, belching and occasionally vomiting, the gut is simply processing food more slowly than it's used to. Diarrhoea and constipation reflect altered gut motility. Fatigue and headache are reported during dose escalation, often transiently. Injection-site reactions are mild and rotate with the injection site.

The side effects that need prompt attention are different in character. The MHRA has highlighted acute pancreatitis as an infrequent but serious risk with GLP-1 medicines: severe, persistent abdominal pain, particularly pain that spreads to the back, warrants urgent medical assessment, don't wait to see if it settles. Gallbladder problems, signs of dehydration from prolonged vomiting, and symptoms of an allergic reaction are also reasons to seek help quickly rather than managing alone. Our FAQs page addresses some of the practical questions that come up most often, including guidance on which fiber supplement tends to work best when taking Wegovy if constipation or digestive changes become a concern. Any suspected side effect can also be reported directly to the MHRA via the Yellow Card scheme, it genuinely helps post-market safety monitoring.

If you've read this far, you probably have more questions than when you started. That's normal, this is a medicine with real depth, and it's reasonable to want to understand it before committing. If you're also researching specific branded formulations, the Hygene Pharma semaglutide page covers what that particular product involves. Check your eligibility and put those questions to a prescriber through a free consultation with nume.